Uncategorized

New York, NY, USA and Paris, France — May 12, 2026 — Rarecells, a pioneer in liquid biopsy technologies for early cancer detection, today announced that its proprietary ISET® diagnostic system has been recognized by the Innovation Value Institute at Maynooth University among the Top 5 Disruptive Health Technologies with the Potential to Change the […]

Hunting the “Invisible Enemy”: Liquid Biopsy and the Stage Zero Revolution Detecting cancer years before it becomes visible through traditional diagnostic tests. This is the wager of Prof. Patrizia Paterlini-Bréchot and the technology that isolates “sentinels” in the bloodstream. By Sergio Gentili (Translated from Italian: https://www.oncolife.it/news/biopsia-liquida/) December 22, 2025 For decades, oncology has operated according

NEW YORK – (March 26, 2025) – Rarecells, Inc., a pioneering company in liquid biopsy, is pleased to announce the appointment of Dr. Neil Kurtz to its Board of Directors. Dr. Kurtz, a renowned healthcare entrepreneur and executive, brings over 40 years of experience in the pharmaceutical, contract research, post-acute care, and medical diagnostic sectors.

NEW YORK, Sept. 6, 2022 /PRNewswire/ — Rarecells, Inc. today announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director. “We are delighted to welcome Neil as Board Director. With his broad understanding of diagnostics and the Liquid Biopsy space he is well-positioned to provide valuable perspectives

We are delighted to join the prestigious The Oncology Think Tank, initiated by Prof. Azra Raza – Director of the MDS Center at Columbia University in New York, USA. We aim to provide patients with blood tests that diagnose cancer well before the moment medical imaging analyses are able to detect the tumor mass, making cancer

Attend the Keynote presentation ”New non-invasive approaches for early diagnosis and follow up of invasive cancers” of Prof. Patrizia Paterlini-Bréchot, CSO of Rarecells Diagnostics, during the 2nd Liquid Biopsies Congress, which will be held virtually and free to attend upon registration. Save the date: Thursday 2020, 08th October at 4:20 pm. For more information and

[OPPORTUNITY] – Rarecells is looking to hire a Research Lab Director! 🧬🦠🔬 For more info: www.rarecells.com/careers

Attend the Keynote presentation ” Clinical Applications of Circulating Tumor Cells in Predictive Oncology ” of Prof. Patrizia Paterlini-Bréchot, CSO of Rarecells Diagnostics, during the Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019 Conference in Rotterdam. Save the date: Wednesday 2019, 30th October at 09:45 am. For more information visit: https://www.selectbiosciences.com/conferences/biographies.aspx?speaker=1472017&conf=EXLBPEU2019

https://actc2019.org Rarecells Diagnostics will be present at the 4th Advances in Circulating Tumor Cells congress, from 2 to 5 October 2019 in Corfu, Greece. We welcome you at our booth #4!

Innovation Forum Follow Prof. Patrizia Paterlini Brechot, Founder & CSO of Rarecells Diagnostics, in the panel discussion “Prevention, early detection and future therapies in oncology” at Health Horizons Future Healthcare Forum in #Cambridge Innovation Forum Find out more here: https://www.horizons.health/